Skip to content

Endometrial Markers in Autoimmune Diseases

Endometrial Markers in Women With Autoimmune Diseases Receiving Assisted Reproduction

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03843034
Enrollment
22
Registered
2019-02-15
Start date
2019-02-18
Completion date
2023-12-31
Last updated
2023-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Diseases, Endometrial Receptivity, Fertility

Brief summary

Autoimmune diseases cause a decreased endometrial receptivity during the implantation window, most likely changing the endometrial cytokines pattern due to dysregulation of the inflammatory processes.Therefore, endometrial cytokine profiles will be compared in women with autoimmune disease and normal, fertile women. The collected endometrial tissue and blood samples will be examined for the cytokines profiling using commercially available ELISA kits. The sample size was calculated choosing, as primary outcome, changes in endometrial LIF concentration between the disease and control Group, which is our main goal. Given a type I error of 5%, a maximum of 21 women are needed for each Group to reach the desired power of 80% to detect the least changes in concentrations.

Interventions

GENETICMeasure endometrial markers

Endometrial biopsies will be taken from participants in both groups

Sponsors

Odense University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

Study group: \* Females with infertility combined with autoimmune disease and in fertility treatment. Control group: \* Female from couples with severe male infertility and in fertility treatment.

Exclusion criteria

* Language problems to such an extent that the subjects do not understand the scope of the study. * Abnormal follicle stimulating hormone (FSH), * Abnormal antral follicles Count * Genital infections * Endometriosis * Tubal occlusion * Polycystic ovarian syndrome

Design outcomes

Primary

MeasureTime frameDescription
Endometrial cytokine LIF concentration (pg/ml)February 18, 2019 - August 31, 2020The endometrial cytokine LIF profile in endometrial biopsies of women with autoimmune disease will be determined and compared to normal, fertile women (pg/mL)

Secondary

MeasureTime frameDescription
Blood concentration of cytokines such as LIF, IL6, TNFα TGFα (pg/ml)February 18, 2019 - August 2020The blood cytokines concentration will be compared between the autoimmune diseases group and the control group. Moreover the cytokines concentration in blood and endometrial tissue will be compared.
endometrial concentration of cytokines such as, IL6, TNFα TGFα (pg/ml)February 18, 2019 - August 2020The endometrial cytokines concentration will be compared between the autoimmune diseases group and the control group. Moreover the cytokines concentration in blood and endometrial tissue will be compared.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026